Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.05 and traded as low as $6.01. Harvard Bioscience shares last traded at $6.01, with a volume of 10,605 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Benchmark decreased their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a report on Friday, March 13th. Wall Street Zen downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. New Street Research set a $6.00 target price on shares of Harvard Bioscience in a research note on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Harvard Bioscience presently has a consensus rating of “Hold” and an average price target of $6.00.

Harvard Bioscience Stock Performance

The company has a market cap of $27.11 million, a P/E ratio of -2.77 and a beta of 1.53. The firm has a 50 day moving average of $5.85 and a 200-day moving average of $6.05. The company has a quick ratio of 1.06, a current ratio of 1.99 and a debt-to-equity ratio of 3.60.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.29. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.The company had revenue of $20.76 million for the quarter, compared to analysts’ expectations of $21.20 million.

Insider Activity

In other Harvard Bioscience news, Director William Snider purchased 8,475 shares of Harvard Bioscience stock in a transaction dated Tuesday, March 17th. The stock was acquired at an average price of $4.85 per share, for a total transaction of $41,103.75. Following the acquisition, the director owned 32,000 shares in the company, valued at $155,200. This trade represents a 36.03% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen J. Denelsky purchased 10,000 shares of Harvard Bioscience stock in a transaction dated Tuesday, March 17th. The stock was acquired at an average price of $4.87 per share, with a total value of $48,700.00. Following the acquisition, the director owned 21,000 shares in the company, valued at approximately $102,270. This represents a 90.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 36,000 shares of company stock worth $177,354. 20.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Harvard Bioscience

Several large investors have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Harvard Bioscience by 44.4% in the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 11,948 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Harvard Bioscience by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock valued at $308,000 after purchasing an additional 18,923 shares in the last quarter. Legato Capital Management LLC raised its holdings in shares of Harvard Bioscience by 210.4% in the 4th quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 29,462 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Harvard Bioscience by 291.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 37,057 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Harvard Bioscience in the 4th quarter valued at about $26,000. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.